CompletedNot Applicable

Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria

Pakistan60 participantsStarted 2025-08-18

Plain-language summary

This study aims to compare the effectiveness and safety of two commonly used antihistamines, bilastine 20 mg and levocetirizine 5 mg, in patients diagnosed with chronic urticaria. Chronic urticaria is a skin condition characterized by recurrent itchy wheals that significantly affect quality of life. Eligible participants will be randomly assigned to receive either bilastine or levocetirizine for a defined treatment period. The severity of symptoms, improvement in itching and wheals, and any adverse effects will be assessed during follow-up visits. The results of this study will help determine which treatment provides better symptom control with fewer side effects in patients with chronic urticaria.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with diagnosis of CSU as per operational definitions. * Patients already taking Bilastine 20 mg and still getting new lesions. * UAS7 score \>3 * Age range of 18-70 years * Both male and female patients Exclusion Criteria: * • women Patients who have already received treatment of CSU other than Bilastine. * Patients taking oral or topical corticosteroids * Pregnant or lactating * Patients with hereditary angioedema, atopic dermatitis, systemic immune disorders, collagen vascular diseases, immunocompromised status, Chronic liver or kidney failures

What they're measuring

change in urticaria severity score (UAS7)

Timeframe: baseline to 6 weeks

Trial details

NCT IDNCT07365683

SponsorDerma Techno Pakistan

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-01-10